Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01408043 · OUTCOME

Overall Survival in Supermobilizers and Normal Mobilizers

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma · Source last updated 2019-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent of participants
Interval / dispersion
Not reported
Time frame
Up to 1 year post-transplant

What was measured

Percentage of participants who were alive 1 year after transplant (OS)

Analysis population: All participants that had some mobilization

Groups in this outcome

Treatment (Stem Cell Supermobilization)

Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Stem Cell Supermobilization)24

Reported measurements

Supermobilizers

Analysis denominator · Participants

GroupSource count
Treatment (Stem Cell Supermobilization)7
Values in percent of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Stem Cell Supermobilization)100Not reportedNot reportedNot reportedNot reported
Normal Mobilizers

Analysis denominator · Participants

GroupSource count
Treatment (Stem Cell Supermobilization)17
Values in percent of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Stem Cell Supermobilization)100Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        100
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      units
      Participants
    title
    Supermobilizers
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        100
    denoms
    1. counts
      1. group Id
        OG000
        value
        17
      units
      Participants
    title
    Normal Mobilizers
denoms
  1. counts
    1. group Id
      OG000
      value
      24
    units
    Participants
description
Percentage of participants who were alive 1 year after transplant (OS)
groups
  1. description
    Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
    id
    OG000
    title
    Treatment (Stem Cell Supermobilization)
param Type
NUMBER
population Description
All participants that had some mobilization
reporting Status
POSTED
time Frame
Up to 1 year post-transplant
title
Overall Survival in Supermobilizers and Normal Mobilizers
type
SECONDARY
unit Of Measure
percent of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice